Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2002 1
2003 1
2005 2
2006 1
2007 4
2008 4
2009 5
2010 4
2011 4
2012 3
2013 5
2014 5
2015 2
2016 3
2017 7
2018 6
2019 4
2020 3
2021 1
2022 2
2023 3
2024 1

Text availability

Article attribute

Article type

Publication date

Search Results

65 results

Results by year

Filters applied: . Clear all
Page 1
Did you mean normal o donovan (172 results)?
Effects of HER Family-targeting Tyrosine Kinase Inhibitors on Antibody-dependent Cell-mediated Cytotoxicity in HER2-expressing Breast Cancer.
Collins DM, Madden SF, Gaynor N, AlSultan D, Le Gal M, Eustace AJ, Gately KA, Hughes C, Davies AM, Mahgoub T, Ballot J, Toomey S, O'Connor DP, Gallagher WM, Holmes FA, Espina V, Liotta L, Hennessy BT, O'Byrne KJ, Hasmann M, Bossenmaier B, O'Donovan N, Crown J. Collins DM, et al. Among authors: o donovan n. Clin Cancer Res. 2021 Feb 1;27(3):807-818. doi: 10.1158/1078-0432.CCR-20-2007. Epub 2020 Oct 29. Clin Cancer Res. 2021. PMID: 33122343 Free PMC article. Clinical Trial.
Alterations in immune cell phenotype and cytotoxic capacity in HER2+ breast cancer patients receiving HER2-targeted neo-adjuvant therapy.
Gaynor N, Blanco A, Madden SF, Moran B, Fletcher JM, Kaukonen D, Ramírez JS, Eustace AJ, McDermott MSJ, Canonici A, Toomey S, Teiserskiene A, Hennessy BT, O'Donovan N, Crown J, Collins DM. Gaynor N, et al. Among authors: o donovan n. Br J Cancer. 2023 Oct;129(6):1022-1031. doi: 10.1038/s41416-023-02375-y. Epub 2023 Jul 28. Br J Cancer. 2023. PMID: 37507543 Free PMC article. Clinical Trial.
Vitamin D analogues: Potential use in cancer treatment.
Duffy MJ, Murray A, Synnott NC, O'Donovan N, Crown J. Duffy MJ, et al. Among authors: o donovan n. Crit Rev Oncol Hematol. 2017 Apr;112:190-197. doi: 10.1016/j.critrevonc.2017.02.015. Epub 2017 Feb 22. Crit Rev Oncol Hematol. 2017. PMID: 28325259 Review.
Survivin: a promising tumor biomarker.
Duffy MJ, O'Donovan N, Brennan DJ, Gallagher WM, Ryan BM. Duffy MJ, et al. Among authors: o donovan n. Cancer Lett. 2007 Apr 28;249(1):49-60. doi: 10.1016/j.canlet.2006.12.020. Epub 2007 Feb 1. Cancer Lett. 2007. PMID: 17275177 Review.
The role of ADAMs in disease pathophysiology.
Duffy MJ, McKiernan E, O'Donovan N, McGowan PM. Duffy MJ, et al. Among authors: o donovan n. Clin Chim Acta. 2009 May;403(1-2):31-6. doi: 10.1016/j.cca.2009.01.007. Clin Chim Acta. 2009. PMID: 19408347 Review.
Survivin: a new target for anti-cancer therapy.
Ryan BM, O'Donovan N, Duffy MJ. Ryan BM, et al. Among authors: o donovan n. Cancer Treat Rev. 2009 Nov;35(7):553-62. doi: 10.1016/j.ctrv.2009.05.003. Epub 2009 Jun 25. Cancer Treat Rev. 2009. PMID: 19559538 Review.
Inhibition of CDK8/19 Mediator kinase potentiates HER2-targeting drugs and bypasses resistance to these agents in vitro and in vivo.
Ding X, Sharko AC, McDermott MSJ, Schools GP, Chumanevich A, Ji H, Li J, Zhang L, Mack ZT, Sikirzhytski V, Shtutman M, Ivers L, O'Donovan N, Crown J, Győrffy B, Chen M, Roninson IB, Broude EV. Ding X, et al. Among authors: o donovan n. Proc Natl Acad Sci U S A. 2022 Aug 9;119(32):e2201073119. doi: 10.1073/pnas.2201073119. Epub 2022 Aug 1. Proc Natl Acad Sci U S A. 2022. PMID: 35914167 Free PMC article.
Role of ADAMs in cancer formation and progression.
Duffy MJ, McKiernan E, O'Donovan N, McGowan PM. Duffy MJ, et al. Among authors: o donovan n. Clin Cancer Res. 2009 Feb 15;15(4):1140-4. doi: 10.1158/1078-0432.CCR-08-1585. Clin Cancer Res. 2009. PMID: 19228719 Review.
EGFR and HER-2 antagonists in breast cancer.
O'Donovan N, Crown J. O'Donovan N, et al. Anticancer Res. 2007 May-Jun;27(3A):1285-94. Anticancer Res. 2007. PMID: 17593621 Free article. Review.
65 results